4.6 Article

The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage

期刊

PLOS ONE
卷 7, 期 4, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0035436

关键词

-

资金

  1. Cancer Research UK [C46/A10588, CA309/A2187, C309/A82741]
  2. NHS
  3. Cancer Research UK [10588, 13407, 11566] Funding Source: researchfish

向作者/读者索取更多资源

Background: Heat shock protein 90 (HSP90) is a molecular chaperone responsible for the conformational maintenance of a number of client proteins that play key roles in cell cycle arrest, DNA damage repair and apoptosis following radiation. HSP90 inhibitors exhibit antitumor activity by modulating the stabilisation and activation of HSP90 client proteins. We sought to evaluate NVP-AUY922, the most potent HSP90 inhibitor yet reported, in preclinical radiosensitization studies. Principal Findings: NVP-AUY922 potently radiosensitized cells in vitro at low nanomolar concentrations with a concurrent depletion of radioresistance-linked client proteins. Radiosensitization by NVP-AUY922 was verified for the first time in vivo in a human head and neck squamous cell carcinoma xenograft model in athymic mice, as measured by delayed tumor growth and increased surrogate end-point survival (p =< 0.0001). NVP-AUY922 was shown to ubiquitously inhibit resolution of dsDNA damage repair correlating to delayed Rad51 foci formation in all cell lines tested. Additionally, NVP-AUY922 induced a stalled mitotic phenotype, in a cell line-dependent manner, in HeLa and HN5 cell lines irrespective of radiation exposure. Cell cycle analysis indicated that NVP-AUY922 induced aberrant mitotic entry in all cell lines tested in the presence of radiation-induced DNA damage due to ubiquitous CHK1 depletion, but resultant downstream cell cycle effects were cell line dependent. Conclusions: These results identify NVP-AUY922 as the most potent HSP90-mediated radiosensitizer yet reported in vitro, and for the first time validate it in a clinically relevant in vivo model. Mechanistic analysis at clinically achievable concentrations demonstrated that radiosensitization is mediated by the combinatorial inhibition of cell growth and survival pathways, ubiquitous delay in Rad51-mediated homologous recombination and CHK1-mediated G(2)/M arrest, but that the contribution of cell cycle perturbation to radiosensitization may be cell line specific.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Systematic review and meta-analysis of occult contralateral nodal metastases in patients with oropharyngeal squamous carcinoma undergoing elective neck dissection

Akshat Malik, John C. Hardman, Yadsan Devabalan, Christopher Nutting, Shreerang Bhide, Kevin Harrington, Clare Schilling, Vinidh Paleri

Summary: A systematic review and meta-analysis was conducted to evaluate occult contralateral nodal metastases (OCM) in patients undergoing bilateral neck dissection for surgically treated oropharyngeal squamous cell carcinoma (OPSCC). The study found that OCM were seen in 9.8% of patients, with a higher rate in cN positive necks compared to cN0 necks. This highlights the importance of considering contralateral neck involvement in the surgical treatment of OPSCC.
Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

Charles M. Rudin, Hardev S. Pandha, Matthew Zibelman, Wallace L. Akerley, Kevin J. Harrington, Daphne Day, Andrew G. Hill, Steven J. O'Day, Timothy D. Clay, Gavin M. Wright, Ross R. Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Jaime R. Merchan, Yixin Ren, Emmett Schmidt, Lisa Guttman, Sumati Gupta

Summary: This study evaluated the efficacy and safety of V937 combined with pembrolizumab in patients with advanced solid tumors. The results showed that the combination therapy had a manageable safety profile, but did not achieve greater efficacy than pembrolizumab monotherapy in non-small cell lung cancer and urothelial cancer.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Review Oncology

Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

Robert I. Haddad, Kevin Harrington, Makoto Tahara, Petr Szturz, Christophe Le Tourneau, Satu Salmio, Marcis Bajars, Nancy Y. Lee

Summary: For the last 20 years, cisplatin-based chemoradiotherapy has been the standard treatment for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) patients at high risk of recurrence. However, many patients are ineligible for this treatment due to various reasons. The criteria for cisplatin ineligibility, including age and renal impairment, are still debated. The proportion of cisplatin ineligible patients with resected LA SCCHN remains unclear. This review discusses cisplatin ineligibility considerations, limited clinical evidence, and ongoing clinical trials for alternative treatment options.

CANCER TREATMENT REVIEWS (2023)

Article Oncology

Predicting Response to Radical Chemoradiotherapy with Circulating HPV DNA (cHPV-DNA) in Locally Advanced Uterine Cervix Cancer

Susan Lalondrelle, Jen Lee, Rosalind J. Cutts, Isaac Garcia Murillas, Nik Matthews, Nicholas Turner, Kevin Harrington, Katherine Vroobel, Emily Moretti, Shreerang A. Bhide

Summary: Human papilloma virus (HPV) is a major cause of cervical cancer, and there is currently no reliable method to predict early relapse. We have developed a blood test that can accurately detect HPV-DNA fragments in the blood, which can be used to assess treatment response and monitor relapse.

CANCERS (2023)

Article Oncology

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

P. Martin, Z. Tsourti, J. Ribeiro, L. Castelo-Branco, E. de Azambuja, S. Gennatas, J. Rogado, M. Sekacheva, S. Susnjal, D. Vinal, R. Lee, S. Khallaf, G. Dimopoulou, S. Pradervand, J. Whisenant, T. K. Choueiri, D. Arnold, K. Harrington, K. Punie, J. Oliveira, O. Michielin, U. Dafni, S. Peters, G. Pentheroudakis, E. Romano

Summary: This paragraph summarizes the results of a study analyzing COVID-19 patients, which found that factors such as symptomatic patients, males, older age, ethnicity other than Asian/Caucasian, Eastern Cooperative Oncology Group performance status >2, body mass index <25, hematological malignancy, progressive disease versus no evident disease, and advanced cancer stage significantly affect COVID-19 outcomes.

ESMO OPEN (2023)

Article Oncology

Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

Simon Crabb, Robin Wickens, Sarah Jane-Bibby, Denise Dunkley, Megan Lawrence, Allen Knight, Robert Jones, Alison Birtle, Robert Huddart, Mark Linch, Jonathan Martin, Adam Coleman, Konstantinos Boukas, Hannah Markham, Gareth Griffiths

Summary: This study aims to evaluate the safety and efficacy of PD-L1 directed immunotherapy atezolizumab in UTSCC patients. Preliminary translational data suggests potential therapeutic value. Through this study, we hope to provide a new treatment option for UTSCC patients.

BMC CANCER (2023)

Article Oncology

Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma

Alexandra J. Rose, Mercedes M. Fleming, Jeffrey C. Francis, Jian Ning, Anton Patrikeev, Ritika Chauhan, Kevin J. Harrington, Amanda Swain

Summary: This study established patient-derived xenograft (PDX) lines and tumor organoid models for salivary gland adenoid cystic carcinoma (ACC), and demonstrated the inhibitory effect of dBET6 on ACC cells. Molecular studies revealed a decrease in BRD4 and MYB protein levels and target gene expression with dBET6 treatment. In vivo experiments showed that dBET6 altered the relative composition of ACC cell types and inhibited their progenitor function.

JOURNAL OF PATHOLOGY (2023)

Review Oncology

The Role of Mucin Expression in the Diagnosis of Oesophago-Gastric Cancer: A Systematic Literature Review

Nikhil Manish Patel, Georgios Geropoulos, Pranav Harshad Patel, Ricky Harminder Bhogal, Kevin Joseph Harrington, Aran Singanayagam, Sacheen Kumar

Summary: Diagnosis of oesophago-gastric cancer is challenging, but non-invasive risk stratification can identify susceptible patients with pre-malignant or benign diseases. Early oesophago-gastric cancer can be treated sooner following diagnostic confirmation through endoscopic biopsy. Mucins, transmembrane glycoproteins implicated in oesophago-gastric cancer, have the potential to be used as biomarkers for malignant transformation. This systematic review examines the role of mucins in the diagnosis of oesophago-gastric cancer.

CANCERS (2023)

Meeting Abstract Oncology

Safety, Efficacy, and Biomarker Assessment of RP1 in Combination With Nivolumab in Patients with Advanced Skin Cancers

Georgia M. Beasley, Ari M. VanderWalde, Tawnya L. Bowles, Joseph J. Sacco, Jiaxin Niu, Katy K. Tsai, Jason A. Chesney, Bartosz Chmielowski, Adel Samson, Terence Duane Rhodes, Gino K. In, Anna C. Pavlick, Trisha M. Wise-Draper, Miguel F. Sanmamed, Jeannie Hou, Mark R. Middleton, Kevin Harrington, Celeste Lebbe, Judith Michels, Mohammed M. Milhem

ANNALS OF SURGICAL ONCOLOGY (2023)

Meeting Abstract Oncology

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)

Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, Robert A. Huddart, Earle F. Burgess, Nadine Houede, Severine Banek, Brigitte Laguerre, Valentina Guadalupi, Ja Hyeon Ku, Spyros Triantos, Sydney Akapame, Kris Deprince, Sutapa Mukhopadhyay, Arlene O. Siefker-Radtke

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Urology & Nephrology

Management of Fibroblast Growth Factor Inhibitor Treatment- emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begona Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot

Summary: This study aimed to understand and manage the treatment-emergent adverse events (TEAEs) of Erdafitinib to optimize fibroblast growth factor receptor inhibitor (FGFRi) treatment. The results showed that early identification and proactive management of select TEAEs can improve or resolve most adverse events in patients, allowing for maximum benefit from FGFRi treatment.

EUROPEAN UROLOGY OPEN SCIENCE (2023)

Article Dentistry, Oral Surgery & Medicine

Head and neck mucosal melanoma: radiological considerations and UK imaging guidelines

Ashwin Algudkar, Kevin Harrington, Cyrus Kerawala, Izhar Bagwan, Derfel Ap Dafydd

Summary: This study summarizes the imaging recommendations and characteristics of head and neck mucosal melanoma (HNMM), and provides revised guidelines to guide the investigation and management of this rare and aggressive cancer.

ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG (2023)

Article Oncology

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence

K. J. Harrington, E. E. W. Cohen, D. Soulieres, J. Dinis, L. Licitra, M. -j. Ahn, A. Soria, J. -p. Machiels, N. Mach, R. Mehra, B. Burtness, R. F. Swaby, J. Lin, J. Ge, N. Lerman, C. Le Tourneau

Summary: Through a study on patients with HNSCC, it was found that pembrolizumab provided longer overall survival and durable responses in all subgroups of recurrence patterns, regardless of previous treatment.

ORAL ONCOLOGY (2023)

Article Urology & Nephrology

Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma

Christian D. Fankhauser, Abolghassem Jandari, Laurence Collette, Torgrim Tandstad, Di Maria Jiang, Ugo De Giorgi, Christopher Sweeney, Angelika Terbuch, Michal Chovanec, Robert Huddart, Carsten Bokemeyer, Jorg Beyer, Silke Gillessen

Summary: Levels of serum tumor markers play a crucial role in determining chemotherapy intensity for testicular cancer patients. Using test results before removal of the cancer-bearing testicle instead of immediately before chemotherapy may result in inadequate treatment.

EUROPEAN UROLOGY OPEN SCIENCE (2023)

暂无数据